NEW YORK (GenomeWeb) – Cancer diagnostics company Empire Genomics announced today that it has received approval from New York State to offer molecular and cellular tumor marker testing through the state's Clinical Laboratory Evaluation Program (CLEP).
The company plans to offer genetic testing and molecular diagnostics to help physicians make treatment decisions for cancer patients. The CLEP program evaluates a clinical lab's ability to accurately and reliably deliver test results.
"The addition of molecular testing solidifies our test menu, allowing us to offer a more complete range of testing needed for personalized diagnostics and therapeutics," said COO John Rushton in a statement.
In December, the firm reported receiving CE Marking for several of its products including fluorescent in situ hybridization probes and karyotyping media.